GAMMA Investing LLC Purchases 26,826 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

GAMMA Investing LLC raised its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 4,003.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,496 shares of the company's stock after acquiring an additional 26,826 shares during the quarter. GAMMA Investing LLC's holdings in Kiniksa Pharmaceuticals International were worth $611,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $61,000. KLP Kapitalforvaltning AS acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $158,000. Bellevue Group AG acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $160,000. Tower Research Capital LLC TRC lifted its holdings in Kiniksa Pharmaceuticals International by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock valued at $168,000 after acquiring an additional 4,575 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in Kiniksa Pharmaceuticals International by 7.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock valued at $215,000 after acquiring an additional 719 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

KNSA has been the subject of a number of research analyst reports. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals International in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price target for the company. Wedbush restated an "outperform" rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Finally, Jefferies Financial Group boosted their price objective on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $38.80.

Insider Activity

In other news, insider Ross Moat sold 18,259 shares of the company's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $20.29, for a total value of $370,475.11. Following the transaction, the insider now owns 9,415 shares in the company, valued at $191,030.35. This represents a 65.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Sanj K. Patel sold 62,116 shares of the company's stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $27.33, for a total value of $1,697,630.28. Following the completion of the transaction, the chief executive officer now owns 96,674 shares in the company, valued at $2,642,100.42. This represents a 39.12% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 440,863 shares of company stock worth $12,101,029 in the last 90 days. Company insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ KNSA traded up $0.51 on Friday, hitting $28.44. 654,925 shares of the company were exchanged, compared to its average volume of 516,264. The company's 50 day moving average price is $25.99 and its 200-day moving average price is $22.40. The firm has a market capitalization of $2.08 billion, a P/E ratio of -113.76 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a twelve month low of $17.38 and a twelve month high of $30.69.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.09. The firm had revenue of $137.79 million for the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The business's revenue for the quarter was up 72.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.25) EPS. As a group, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.